Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report 2026

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Overview

• Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) market size has reached to $6.92 billion in 2025 • Expected to grow to $21.35 billion in 2030 at a compound annual growth rate (CAGR) of 24.6% • Growth Driver: Rising Cancer Rates Drive Growth In Cell And Gene Therapy CDMO Market • Market Trend: Advancements In Cell And Gene Therapy Manufacturing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations offer services tailored to the unique needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs play a critical role in accelerating the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services to support their clients' needs from early-stage development through commercialization. The main product types of cell and gene therapy contract development and manufacturing organization (CDMO) are gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves modifying or manipulating the genes within a person's cells to treat or prevent disease. Various phases include phase 1, phase 2, phase 3, and phase 4 for different indications, such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

What Is The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Growth Forecast?

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is expected to see exponential growth in the next few years. It will grow to $21.35 billion in 2030 at a compound annual growth rate (CAGR) of 24.6%. The growth in the forecast period can be attributed to increasing commercialization of gene-modified therapies, rising demand for flexible manufacturing capacity, expansion of global cdmo partnerships, growing investment in cell therapy pipelines, increasing regulatory approvals for advanced therapies. Major trends in the forecast period include expansion of end-to-end cdmo service offerings, growing demand for commercial-scale manufacturing support, rising adoption of advanced gene editing platforms, increasing focus on accelerated development timelines, enhanced integration of regulatory support services.

Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Segmentation

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy 2) By Phase: Phase 1, Phase 2, Phase 3 3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications Subsegments: 1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy 2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy 3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

What Is The Driver Of The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The growing prevalence of cancer cases is expected to propel the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market going forward. Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells in the body. The growing prevalence of cancer cases is due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. Cell and gene therapy contract development and manufacturing organization (CDMO) helps reduce cancer prevalence by developing and manufacturing innovative, targeted treatments that enhance efficacy and patient outcomes. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the growing prevalence of cancer cases drives the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) industry.

Key Players In The Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

Major companies operating in the cell and gene therapy contract development and manufacturing organization (cdmo) market are Lonza Group, Catalent Inc, Thermo Fisher Scientific Inc, Samsung Biologics Co Ltd, WuXi Biologics, AGC Biologics, FUJIFILM Diosynth Biotechnologies, Oxford BioMedica Plc, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Avid Bioservices Inc, Charles River Laboratories International Inc, VGXI Inc, Genezen Laboratories Inc, OmniaBio Inc, Pluri Inc, Cell and Gene Therapy Catapult, BioVectra Inc, Porton Advanced Solutions Ltd

Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends and Insights

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are focused on expanding their portfolio with advanced solutions such as PluriMatrix technology to enhance the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system tailored for the large-scale production of cell-based products. This advanced technology facilitates the 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For instance, in January 2024, Pluri, an Israel-based biotech company, launched PluriCDMO, a new business division that offers cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). The new division includes a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly established division offers end-to-end services from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as detailed in a company announcement. It leverages the company's cutting-edge PluriMatrix technology to offer advanced cell therapy manufacturing services.

What Are Latest Mergers And Acquisitions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

In November 2023, Ajinomoto Co. Inc., a Japan-based food and biotechnology corporation, acquired Forge Biologics for $620 million. Through this acquisition, Ajinomoto bolsters its global capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, enriching and fortifying its existing contract development and manufacturing services. Forge Biologics is a US-based gene therapy contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company.

Regional Outlook

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report 2026?

The cell and gene therapy contract development and manufacturing organization (cdmo) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (cdmo) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.